BioSpace15h
SpringWorks Wins FDA Nod for Neurofibromatosis Drug, Tees Up Challenge to AstraZeneca
The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...
Health companies return $2.6 trillion to shareholders over time amid rising medical costs
Payouts to shareholders of large publicly traded health companies more than tripled over the past two decades, new research ...
GlobalData on MSN17h
FDA approves Gomekli as first neurofibromatosis drug for adults
The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...
MM&M10h
Will pharma’s loyalty to linear TV begin to fade in 2025?
As advertisers pay more for an ever-scarcer supply of ratings points, pharma’s ironclad devotion to TV could finally be in ...
US pharma giant Merck backs healthcare marketplace HD in Southeast Asia
Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...
BioSpace19h
New M&A Action, BMS’ Ongoing Cost Cuts and the Insatiable Demand for Weight Loss Drugs
Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...
Le Lézard14h
HR Conference of the Year: World's Leading Brands Drive 90% of Sessions at IAMPHENOM
Phenom, an AI company specializing in HR, today announced 42 additions to its rapidly expanding IAMPHENOM 2025 speaker lineup ? building on the momentum of the industry's only human resources ...